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Abstract
Background: Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine upstream of many
inflammatory cytokines. MIF is implicated in several acute and chronic inflammatory conditions. MIF’s promoter
region has functional single nucleotide polymorphisms that controls MIF expression and protein levels. Since
increased plasma MIF levels are associated with cancer, studies have examined the association between Mif
promoter polymorphisms and cancer. This study is a meta-analysis of the available studies on such an association.
Results: A total of 5 studies were included in this meta-analysis to include 1116 cases (cancer patients) and 1728
controls (no cancer). Carrying any C allele in the Mif -173 G/C promoter polymorphism resulted in a significantly
greater risk for developing cancer [OR = 1.89 (1.15-3.11), p = 0.012)] when compared to the (G/G) genotype.
Subgroup analysis revealed that this association was significant only for “solid” tumors (including gastric and
prostate cancers) [OR = 2.67 (1.26-5.65), p = 0.010] but not for “non-solid” tumors (leukemia) [OR = 1.21 (0.95-1.55),
p = 0.122]. Furthermore, when only prostate tumor studies were included in the analysis, the association became
even stronger [OR = 3.72 (2.55-5.41), p < 0.0001].
Conclusions: Meta-analysis suggests there is an association between any C allele in the Mif -173 G/C promoter
polymorphism and an increased risk of cancer, particularly for solid tumors. The association appeared stronger for
prostate cancer, specifically. Future studies that include different types of cancers are needed to support and
extend these observations.
Background
Macrophage migration inhibitory factor (MIF) was the
first cytokine identified nearly 50 years ago. At that time
its described activity was as a soluble factor produced by
T-lymphocytes that inhibited the directed migration of
macrophages [1]. Since then, MIF is documented to be
expressed by a broad variety of cells and tissues, includ-
ing immune and non-immune cells [2,3]. Presently, MIF
is considered a pleiotropic cytokine that is a central reg-
ulator of innate immunity and a regulator of inflamma-
tion since it is constitutively expressed and acts as an
upstream regulator of many other inflammatory cyto-
kines [4]. Experimental evidence has shown that MIF
plays a critical role in immune and inflammatory
diseases including sepsis [5], rheumatoid arthritis [6],
delayed-type hypersensitivity [7], Crohn’s disease [8] and
gastric ulcer formation [9].
Because MIF is an important regulator of inflammation
and given the established link between chronic inflamma-
tion and cancer [10], recent studies have examined the
link between Mif mRNA expression and/or MIF protein
levels and cancer [11]. Increased Mif mRNA expression
in prostate tissue [12] and increased serum MIF protein
levels [13] were first documented for prostate cancer
patients. Other investigations corroborated these findings
for prostate cancer [14,15] and extended the association
between increased Mif mRNA and/or protein expression
to other types of cancer [16-19]. Therefore, strong evi-
dence has accumulated suggesting that MIF is an impor-
tant link between inflammation and cancer [11]. Two
regions within the Mif promoter contain functional poly-
morphisms that result in variable Mif mRNA amounts
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promoter polymorphism genotypes are associated with
increased risk of inflammatory disease [20,21]. A -173 G/
C transversion results in a single nucleotide polymorph-
ism (SNP) that was first described with higher frequency
in arthritis patients [22,23]. Another functional promoter
polymorphism was identified at position -794, where
increasing copies of a CATT tetranucleotide repeat (5 to
8 copies, -794 CATT(5-8)) were also associated with
increased disease severity in arthritis [20]. The associa-
tion between these polymorphisms and disease has been
extended to other inflammatory conditions including
ulcerative colitis [24], peptic ulcer disease [25] and
increased morbidity due to sepsis [26]. These studies
thus suggest that an association exists between Mif pro-
moter genotypes that result in increased MIF protein
production and an increased risk of inflammatory dis-
ease. Similarly, studies examining the association between
Mif promoter polymorphisms and cancer have reported
an increased risk of cancer for patients with higher MIF
protein producing promoter genotypes [3,27-30] while
others have reported a lack of association [31]. The aim
of this study is to conduct a meta-analysis of all available
studies that examine the association between Mif promo-
ter polymorphism and the incidence of cancer.
Results
Studies Eligibility
After a literature search and selection based on inclu-
sion criteria as described in the methods, five studies
were identified for meta-analysis [27-31]. Table 1 lists
these studies and their characteristics. The data for the
meta-analysis included 1,116 cancer cases and 1,728
controls (no cancer). Mif -173 G/C polymorphism
groups were divided as G/G (control comparison) and
any C/X (i.e. G/C or C/C). All studies were published
between 2005 and June 2011. Two studies were con-
ducted on leukemia patients and were thus classified as
“non-solid tumors” whereas the remaining three studies
examined either gastrointestinal or prostate tumors and
thus were classified as “solid tumors”.
Meta-analysis results
Meta-analysis of the 5 eligible studies showed that indi-
viduals that carry any C allele in the Mif promoter
region at position -173 had a significantly higher risk for
developing cancer when compared to those that had the
G/G genotype [OR = 1.89 (1.15-3.11), p = 0.0116]. How-
ever, the heterogeneity was very large (I
2 = 87.8%, p <
0.001; Figure 1). Subgroup analysis showed that in
patients with “Non-solid” tumors, there was no signifi-
cant association between the C/X genotype and cancer
[OR = 1.21 (0.95-1.55), p = 0.122; Figure 1], while a sig-
nificant association was still detected for patients with
“Solid” tumors [OR = 2.67 (1.26-5.65), p = 0.0105; Fig-
u r e1 ] .S i n c ee v e nw i t h i nt h e“Solid” tumor subgroup,
heterogeneity was still very large (I
2 = 89.8%, p < 0.001),
further subgrouping to only those studies dealing with
prostate cancer was carried out. When limiting the ana-
lysis to only prostate cancer studies, the heterogeneity
decreased substantially to low levels (I
2 = 22.7%, p =
0.250) and the association between the C genotype of
the Mif promoter polymorphism and cancer was even
greater [OR = 3.72 (2.55-5.41), p < 0.0001].
Discussion
Macrophage migration inhibitory factor is a pro-inflam-
matory cytokine shown to be upstream of and able to
upregulate the production of other inflammatory cyto-
kines [4]. Consequently, MIF is a central modulator of
inflammation and a possible link between chronic
inflammation and cancer [10]. Several studies have
examined the relationship between increased Mif mRNA
expression and cancer [12-19]. Mif promoter poly-
morphisms that increase Mif mRNA expression also
result in increased MIF protein production [21,27] and
recent studies have established an association between
increased MIF serum levels and increased risk for can-
cer [13,14,32]. The association between high expressing
functional Mif promoter polymorphisms and prostate
cancer appears biologically plausible in view of the
documented association between elevated serum MIF
protein levels and prostate cancer. MIF’s ability to over-
ride p53 tumor suppressor activity, sustain MAP (ERK-
1/2) kinase phosphorylation and induce the formation of
other proinflammatory mediators within the tumor
microenvironment [33-36] likely contribute to tumor
promotion. The present meta-analysis study is the first,
to our knowledge, to critically review published studies
on the association between Mif promoter polymorph-
isms and the incidence of cancer. Our meta-analysis
focused on the (-173 G/C) Mif promoter region poly-
morphism and cancer since very few studies have
Table 1 Studies included in meta-analysis
Studies Year Cases
(Cancer)
Controls
(No cancer)
Tumor Type
Any C G/G Any C G/G
Ziino 2005 34 117 78 277 Leukemia
Meyer-Siegler 2007 76 55 29 99 Prostate
Arisawa 2008 106 123 167 261 Gastric
Ding 2008 93 166 45 256 Prostate
Xue 2010 110 228 147 369 Leukemia
Studies were selected from published articles gathered from a search of the
literature using PubMed and meeting the selection criteria (as listed in
Methods).
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CATT repeats and cancer. From the 5 studies included
in our analysis, our results showed that there is a signifi-
cant association between having any C allele at the -173
site within the Mif promoter and cancer. Because of
large heterogeneity in the results, further sub-group ana-
lysis showed that there is a strong association between
Mif promoter genotypes containing a C allele and the
development of solid tumors [OR = 2.67 (1.26-5.65), p =
0.0105], while no association was observed in non-solid
tumors [OR = 1.21 (0.95-1.55), p = 0.122]. Lastly, analy-
sis of studies dealing only with prostate cancer patients
showed the strongest association between cancer inci-
dence and the C allele Mif promoter genotype [OR =
3.72 (2.55-5.41)]. Thus, Mif promoter genotype may
serve as a useful prostate cancer risk marker.
Some limitations of this meta-analysis study should be
considered. First, the number of studies included was
low, reflecting the small number of published studies.
Second, heterogeneity was large in the global analysis,
which justified subgroup analysis but made the number
of studies in each subgroup even smaller. Given these
two limitations, the link between the C allele Mif pro-
moter genotype and prostate cancer awaits validation by
future studies. Similarly, whether this link also extends
to other solid tumors needs to assessed by future stu-
dies. Third, the analysis was based on individual unad-
justed OR from each of the studies included, while a
better estimate may be obtained by adjusting for
potentially contributing factors. For example, Arisawa et
al [28] reported an association between the -173C Mif
allele and gastric cancer only in patients older than 60
years. Therefore, the inclusion of other factors (such as
age) may yield a more accurate estimate of the associa-
tion. Finally, the focus of the current analysis was lim-
ited to the Mif - 1 7 3G / Cp r o m o t e ra n dd i dn o ti n c l u d e
-794 CATT repeat polymorphisms due to the very small
numbers of studies. Two recent studies described an
association between higher MIF producing genotypes
(greater number of CATT repeats) and gastric [28] and
prostate cancer [27] respectively. These observations
should be confirmed by additional studies and the rela-
tionship between the two functional Mif promoters and
carcinogenesis remains to be investigated.
Conclusions
The current meta-analysis results suggest that the -173C
Mif promoter polymorphism is associated with an
increase in the risk of solid tumor cancer, particularly
for prostate cancer. More studies that include a larger
variety of cancers are needed to confirm the association
of high expressing Mif promoter polymorphisms and
prostate cancer.
Methods
Identification and selection of relevant studies
In order to identify all published articles that examined
the association between Mif promoter polymorphisms
Study
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Figure 1 Meta-analysis of Mif promoter region polymorphism (-173 G/C) and cancer. Point estimates of the Odds Ratio (OR) and
accompanying 95% confidence intervals are shown for each study. Overall analysis using Random effects model and subgroup analyses for
patients with “Non-Solid” vs. “Solid” tumors are shown.
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PubMed database through June 2011 using the following
MeSH terms and Keywords: ‘Macrophage migration
inhibitory factor’, ‘polymorphism’ and ‘cancer’ or ‘neo-
plasm’. Studies were included in the meta-analysis if
they met the following criteria: (a) case-control cancer
study, (b) cancer diagnosis was confirmed pathologically,
and (c) written in English.
Data extraction
The two investigators independently examined the list of
studies for inclusion eligibility, extracted data and
reached a consensus on all the items. Meta-analysis was
restricted to examining the results of studies dealing
with the -173 G/C SNP since few studies examined -794
CATT repeat. The following information was extracted
from each eligible study: first author, year of publication,
number of cases and controls, Mif polymorphisms
divided as: GG, any C (CC and CG) for cases and con-
trols, type of cancer: either solid tumor or non-solid
tumor.
Statistical Analysis
The effect of association between Mif polymorphism
(G/G vs any C; i.e. C/G, C/C) and cancer was calcu-
lated as odds ratio (OR) with the corresponding 95%
confidence interval [37]. The summary effect was cal-
c u l a t e du s i n gt h eR a n d o mE ffects (RE; Dersimonian
and Laird) model [38]. Heterogeneity between studies
was assessed using the Q-test and the I
2 test [39]. Het-
erogeneity was classified as: low heterogeneity (I
2 <
25%); moderate (I
2 = 25-50%) or large (I
2 > 50%). Het-
erogeneity was considered statistically significant at
p < 0.05. Sub-group analysis further examined the
effects in studies investigating non-solid tumors vs.
solid tumors. Statistical analysis was conducted using
R (version 2.12; http://www.r-project.org) and the meta
[40] and metafor [41] packages.
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